Oric Pharmaceuticals (ORIC) announced data from a Phase 1b trial of enozertinib at the ESMO Asia Congress 2025. Data in previously treated NSCLC patients with HER2 exon 20 mutations were presented at a poster session. Enozertinib was well tolerated with mostly Grade 1 or 2 treatment-related adverse events and no significant off-target toxicities. Most frequent TRAEs included paronychia, diarrhea, and dermatitis acneiform. Only two patients discontinued treatment due to TRAEs. Higher rates of dose reductions occurred in the 120 mg cohort compared to the 80 mg cohort. Tumor responses were observed in both the 80 mg and 120 mg cohorts, including in patients with baseline brain metastases. Patients in the 80 mg cohort experienced deeper tumor regressions potentially due to the lower rate of dose reductions. The company noted 35% ORR and 100% DCR in the 80 mg cohort. As of the data cutoff, 32% of patients remained on treatment in both the 80 mg and 120 mg cohorts.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals initiated as Early Stage Biotech at Goldman Sachs
- Buy Rating for Oric Pharmaceuticals: Promising Developments and Enozertinib’s Potential in NSCLC Treatment
- Oric Pharmaceuticals initiated with an Outperform at Evercore ISI
- Promising Potential of Oric Pharmaceuticals’ ORIC-944 in Prostate Cancer Market Drives Buy Rating
- Oric Pharmaceuticals price target raised to $20 from $17 at JPMorgan